结肠活检组织学特征(Geboes评分)与活检后前36个月溃疡性结肠炎进展相关
该研究分析葡萄牙13家炎症性肠病中心399例无症状溃疡性结肠炎患者,评估基线Geboes评分与疾病进展的关系。Geboes评分>2B.0、>3.0或>4.0的患者在活检后36个月内疾病进展更早,校正后风险比分别为2.021、2.007和2.349。结论认为Geboes评分是溃疡性结肠炎进展的独立危险因素。
要点
- Geboes评分>2B.0、>3.0或>4.0的无症状UC患者,活检后36个月内疾病进展更早、更频繁。
- 校正Mayo内镜子评分和粪钙卫蛋白后,Geboes评分>2B.0、>3.0、>4.0的HR分别为2.021、2.007、2.349。
- 粪钙卫蛋白<150 μg/g的患者中亦观察到相似结果。
核心结论
- 结肠活检组织学特征(Geboes评分)是溃疡性结肠炎活检后前36个月进展的独立危险因素。
研究设计与样本
- 研究分析ACERTIVE研究中399例无症状溃疡性结肠炎患者的数据,随访至2019年12月31日,来自葡萄牙13家炎症性肠病中心。
- 所有患者在样本采集后24小时内接受乙状结肠镜检查,评估基线Mayo内镜子评分、2份乙状结肠和2份直肠活检的Geboes评分及粪钙卫蛋白浓度。
主要发现
- Geboes评分>2B.0、>3.0或>4.0的患者较Geboes评分≤2B.0、≤3.0或≤4.0的患者,溃疡性结肠炎进展频率更高、进展时间更短(P < .001)。
- 活检后前36个月内,Geboes评分>2B.0较≤2B.0的进展风险HR为2.021(95% CI,1.158-3.526)。
- 活检后前36个月内,Geboes评分>3.0较≤3.0的进展风险HR为2.007(95% CI,1.139-3.534)。
- 活检后前36个月内,Geboes评分>4.0较≤4.0的进展风险HR为2.349(95% CI,1.269-4.349)。
- 粪钙卫蛋白浓度低于150 μg/g的患者中亦发现相似结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In addition to findings from endoscopy, histologic features of colon biopsies have been associated with outcomes of patients with ulcerative colitis (UC). We investigated associations between Geboes scores (a system to quantify structural changes and inflammatory activity in colon biopsies) and UC progression, and the time period over which this association is valid. METHODS: We analyzed data from 399 asymptomatic patients with UC enrolled in the ACERTIVE study, followed at 13 inflammatory bowel disease (IBD) centers in Portugal through 31 December 2019. Blood and stool samples were collected and analyzed, and all patients underwent sigmoidoscopy within 24 h of sample collection. We assessed baseline endoscopic status (Mayo endoscopic subscore), histologic features of 2 sigmoid and 2 rectal biopsies (Geboes score), and concentration of fecal calprotectin (FC). The primary outcome was UC progression (surgical, pharmacologic, and clinical events). We generated survival curves for 36 months or less and more than 36 months after biopsy according to Geboes score using the Kaplan-Meier method and compared findings with those from a log rank test. Cox regression was adjusted for Mayo endoscopic subscore, Geboes score, and level of FC; results were expressed as adjusted hazard ratios (HR) with 95% CIs. RESULTS: Patients with Geboes scores >2B.0, Geboes scores >3.0, or Geboes scores >4.0 had a higher frequency of, and a shorter time to UC progression, than patients with Geboes scores ≤2B.0, Geboes scores ≤3.0, or Geboes score ≤4.0 (P < .001). Disease progression occurred earlier in patients with Geboes scores >2B.0, Geboes scores >3.0, or Geboes scores >4.0 compared with patients with Geboes scores ≤2B.0 (HR, 2.021; 95% CI, 1.158-3.526), Geboes scores ≤3.0 (HR, 2.007; 95% CI, 1.139-3.534), or Geboes scores ≤4.0 (HR, 2.349; 95% CI, 1.269-4.349), respectively, in the first 36 months after biopsy. Similar results were found for patients with concentrations of FC below 150 μg/g. CONCLUSIONS: We found histologic features of colon biopsies (Geboes score) to be an independent risk factor for progression of UC in the first 36 months after biopsy.
引用
- Magro F, Alves C, Lopes J, et al. Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. Clin Gastroenterol Hepatol. 2020. PMID: 32920215. doi:10.1016/j.cgh.2020.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。